What pain management calculators cover
Pain is one of the most common reasons people seek medical care, and its treatment sits at a difficult intersection: undertreated pain ruins lives, while the medicines used to treat it, particularly opioids and anti-inflammatories, carry real risks. The calculators in this library support the quantitative side of safe prescribing. They answer questions such as: what is this patient's total daily opioid load, what dose of a different opioid gives equivalent relief, how should a long-term regimen be reduced gradually, how should neuropathic pain medicines be started and adjusted, and is this patient at risk of kidney injury from an NSAID.
The MME calculator is the starting point. MME stands for morphine milligram equivalents, a standardised unit that converts every opioid in a regimen into the equivalent daily dose of oral morphine. A patient taking oxycodone, a fentanyl patch and occasional tramadol cannot be assessed by adding milligrams together, because the drugs differ in potency. Converted to MME per day, the total becomes comparable against the widely cited caution thresholds in prescribing guidance, and changes over time can be tracked on a single scale.
The opioid conversion calculator handles switching. When pain is poorly controlled, side effects are intolerable, or the formulation no longer suits the patient, prescribers rotate to a different opioid. Equianalgesic tables estimate the dose expected to give similar relief, but the tables are approximate and tolerance does not transfer completely between drugs, so the calculated dose is a starting point for clinical judgement rather than a precise answer. The opioid tapering calculator supports the opposite journey: building a gradual dose reduction schedule for patients on long-term therapy, with the slow stepwise decreases that guidance recommends.
Two further tools cover non-opioid prescribing. The neuropathic pain dosing planner walks through first-line drug titration for nerve pain, including the renal dose adjustments that medicines such as gabapentinoids require in kidney impairment. The NSAID renal risk checklist prompts a structured review of acute kidney injury risk factors before an anti-inflammatory is started or continued. Together, the five tools cover the core arithmetic of pain prescribing: how much, what equivalent, how to reduce, how to titrate, and when to worry.
When clinicians and students use these tools
In primary care, the MME calculator is used during medication reviews for patients on long-term opioids. A GP reviewing a patient on multiple opioid preparations can convert the regimen to a daily MME total in seconds, compare it with the caution thresholds, and use the number to frame a conversation about whether the current regimen is still appropriate. Pharmacists use the same calculation when checking prescriptions, and it is a standard part of opioid stewardship in many health systems.
Opioid rotation happens in general practice, palliative care and pain clinics. A typical scenario: a patient on high-dose morphine has persistent nausea despite antiemetics, and the team decides to switch to oxycodone. The conversion calculator estimates the equianalgesic dose, the prescriber adjusts for incomplete cross-tolerance and the patient's frailty, and the new regimen is started with a plan for close follow-up. In palliative care, where doses can be high and changes frequent, this calculation is routine.
Tapering schedules are built in primary care and pain clinics, often over months. The tapering calculator turns a percentage-based reduction plan into a concrete schedule the patient can follow, showing each step down and the expected timeline. The neuropathic pain planner is used when starting treatment for diabetic neuropathy, postherpetic neuralgia or other nerve pain, where slow titration to an effective dose, with adjustment for kidney function, is the standard approach. The NSAID checklist fits anywhere anti-inflammatories are prescribed: general practice, rheumatology, orthopaedics and emergency departments, where a quick risk review before prescribing can prevent admissions for acute kidney injury.
How to interpret results and what the scores change in practice
The MME total is interpreted against widely cited thresholds from opioid prescribing guidance. Doses around 50 MME per day are commonly treated as a point for extra caution: reassess the benefits and harms, review the pain diagnosis, and consider whether the regimen can be optimised. Doses of 90 MME per day or more are widely cited as a level to avoid escalating to without careful justification, because overdose risk climbs with dose. These are not hard ceilings; a palliative care patient may appropriately be on far higher doses. They are prompts for review, and what changes in practice is the intensity of monitoring, the discussion of naloxone supply, and the consideration of tapering or rotation.
An opioid conversion result is a starting estimate. Standard practice is to reduce the calculated equianalgesic dose, often substantially, to allow for incomplete cross-tolerance, then titrate against pain and side effects. The reduction is larger when switching at high doses, when the patient is older or frail, or when there is renal or hepatic impairment. The result changes the prescription that is written, but the prescriber's judgement sets the final number and the follow-up plan.
A tapering schedule changes the conversation with the patient. Instead of an abstract instruction to reduce gradually, the patient gets a dated plan: this dose until this date, then this dose. Widely cited guidance suggests slow tapers for long-term therapy, often around 10 percent per month or slower, with the freedom to pause if withdrawal symptoms emerge. Faster tapers are reserved for specific situations. The schedule should always be agreed with the patient, because imposed tapers damage trust and outcomes.
The neuropathic pain planner produces a titration path: starting dose, increments, target range and renal adjustments. The NSAID checklist produces a risk profile: if several risk factors are present, the prescriber may choose paracetamol, a topical NSAID, physiotherapy or another strategy instead, or use the lowest effective systemic dose for the shortest time with kidney function monitoring. In each case the tool structures a decision the clinician already owns.
Limitations and pitfalls
Equianalgesic tables are the weakest link in this library, and they should be treated with respect. Published conversion ratios differ between sources, they are derived largely from single-dose studies in opioid-naive patients, and they translate poorly to chronic therapy, to very high doses and to certain drugs such as methadone and buprenorphine, whose pharmacology breaks the simple ratio model. A conversion calculator cannot replace knowledge of the specific drugs involved, and any switch needs close follow-up with rescue arrangements.
MME itself has limits. It measures dose, not risk: a patient on 60 MME with sleep apnoea, benzodiazepine co-prescription and alcohol use may be at far greater risk than a patient on 100 MME without those factors. The thresholds are population-level guides, and applying them rigidly has in some settings led to forced tapers that harmed patients. The number informs judgement; it must not replace it.
Tapering calculators produce arithmetic schedules, but real tapers are clinical processes. Pain may flare, mood may dip, and life events intervene; the schedule must bend. Tapering without addressing the underlying pain, without psychological support where needed, and without the patient's genuine agreement tends to fail. The NSAID checklist, meanwhile, identifies risk factors but does not quantify absolute risk for an individual, and it does not cover the gastrointestinal and cardiovascular risks of NSAIDs, which need separate consideration. None of these tools should be used by patients to adjust their own medicines: opioid changes without medical supervision can precipitate withdrawal or overdose.
How to use this library
Start from the prescribing task. Reviewing a regimen points to the MME calculator; switching opioids points to the conversion calculator; reducing long-term therapy points to the tapering calculator; starting nerve pain treatment points to the dosing planner; prescribing an anti-inflammatory points to the renal risk checklist. Enter complete and current medicines, read the result as a structured starting point, apply clinical judgement for the individual patient, and document both the calculation and the decision. Revisit the numbers whenever the regimen changes.
Related specialities
Frequently asked questions
What is MME and why does it matter?
MME stands for morphine milligram equivalents: a standardised way of expressing the total daily opioid dose as the equivalent amount of oral morphine. Because different opioids have different potencies, MME lets prescribers compare regimens and judge risk on a single scale. Widely cited prescribing guidance treats daily doses around 50 MME as a point for extra caution and reassessment, and advises avoiding increases to 90 MME per day or more without careful justification, because overdose risk rises with dose.
Why convert between opioids instead of just switching doses?
Different opioids differ in potency, duration and how completely they cross-tolerate with each other. An equianalgesic conversion estimates the dose of the new opioid expected to give similar pain relief to the current one. Because published conversion tables are approximate and individual response varies, prescribers usually reduce the calculated dose to allow for incomplete cross-tolerance, especially when switching at higher doses or in patients with risk factors.
How quickly should long-term opioids be tapered?
There is no single correct speed; tapering is individualised. Widely cited guidance recommends slow tapers for people on long-term therapy, often around 10 percent of the dose per month or slower, with pauses if withdrawal symptoms or pain crises occur, and faster tapers only in specific situations such as after surgery or when there is urgent risk. Tapering should be collaborative, with the patient agreeing the plan, and support for pain, mood and function throughout.
What is the NSAID renal risk checklist for?
Non-steroidal anti-inflammatory drugs can reduce blood flow to the kidneys and cause acute kidney injury, particularly in susceptible people. The checklist prompts prescribers to look for the main risk factors before prescribing or continuing an NSAID: older age, chronic kidney disease, dehydration, heart failure, liver disease, and concurrent diuretics, ACE inhibitors or angiotensin receptor blockers. When several risk factors cluster, the prescriber may choose a different analgesic, use the lowest effective dose for the shortest time, or monitor kidney function.
Are these pain calculators for patients or for clinicians?
They are designed primarily for prescribers: doctors, pharmacists, nurse prescribers and pain specialists who manage analgesic regimens. Patients and carers may use them to understand concepts their clinician has discussed, such as what MME means or why a taper is structured a certain way, but no one should start, change or stop opioid or other pain medicines based on a calculator alone. Always follow the plan agreed with the prescriber.